{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:34:01Z","timestamp":1767911641059,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10157-025-02757-x","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:57:07Z","timestamp":1756929427000},"page":"1394-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sodium glucose co-transporter 2 inhibitors (SGLT2Is) effect on erectile dysfunction (ED) in patients with chronic kidney disease (CKD)"],"prefix":"10.1007","volume":"29","author":[{"given":"Amr Mohamed","family":"Shaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehal Kamal","family":"Rakha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Keshk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usama A. Sharaf","family":"El Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2757_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"2757_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5527\/wjn.v4.i3.379.PMID:26167462;PMCID:PMC4491929","volume":"4","author":"E Papadopoulou","year":"2015","unstructured":"Papadopoulou E, Varouktsi A, Lazaridis A, Boutari C, Doumas M. Erectile dysfunction in chronic kidney disease: from pathophysiology to management. World J Nephrol. 2015;4(3):379\u201387. https:\/\/doi.org\/10.5527\/wjn.v4.i3.379.PMID:26167462;PMCID:PMC4491929.","journal-title":"World J Nephrol"},{"issue":"9","key":"2757_CR3","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1093\/ndt\/gfs135","volume":"27","author":"M Vecchio","year":"2012","unstructured":"Vecchio M, Palmer SC, Tonelli M, Johnson DW, Strippoli GFM. Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet need. Nephrol Dial Transplant. 2012;27(9):3420\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfs135.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2757_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2215\/CJN.00990207","volume":"2","author":"SD Weisbord","year":"2007","unstructured":"Weisbord SD, Fried LF, Mor MK, Resnick AL, Unruh ML, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2(5):960\u20137. https:\/\/doi.org\/10.2215\/CJN.00990207. (Epub 2007 Aug 8).","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2757_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1524-6175.2005.05285.x","volume":"8","author":"M Doumas","year":"2006","unstructured":"Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359\u201364. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.05285.x. (PMID: 16687945; PMCID: PMC8109585).","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2757_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/117739280700200012","volume":"2","author":"A Konstantinopoulos","year":"2007","unstructured":"Konstantinopoulos A, Giannitsas K, Raptis S, Perimenis P. Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives. Drug Target Insights. 2007;2:111\u20137.","journal-title":"Drug Target Insights."},{"issue":"7","key":"2757_CR7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463\u201376. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2757_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-022-00975-x","volume":"15","author":"WH Tang","year":"2023","unstructured":"Tang WH, Yu TH, Lee HL, Lee YJ. Interactive effects of intrinsic capacity and obesity on the KDIGO chronic kidney disease risk classification in older patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2023;15(1):1. https:\/\/doi.org\/10.1186\/s13098-022-00975-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"4S","key":"2757_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"22","key":"2757_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720. (Epub 2015 Sep 17. PMID: 26378978).","journal-title":"N Engl J Med"},{"issue":"7","key":"2757_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925. (Epub 2017 Jun 12. PMID: 28605608).","journal-title":"N Engl J Med"},{"issue":"4","key":"2757_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"24","key":"2757_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744. (et al. CREDENCE Trial Investigators).","journal-title":"N Engl J Med"},{"key":"2757_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"2757_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"key":"2757_CR16","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.cpcardiol.2024.102524","volume":"49","author":"FR Alsereidi","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, Gupta A, Al-Rawi AM, Ramadan MM, et al. Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement. Curr Probl Cardiol. 2024;49:102524. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102524.","journal-title":"Curr Probl Cardiol"},{"issue":"13","key":"2757_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137274","volume":"25","author":"N Mylonas","year":"2024","unstructured":"Mylonas N, Nikolaou PE, Karakasis P, Stachteas P, Fragakis N, Andreadou I. Endothelial protection by sodium-glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies. Int J Mol Sci. 2024;25(13):7274. https:\/\/doi.org\/10.3390\/ijms25137274.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2757_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1215\/S1152851705000232","volume":"7","author":"G Bergers","year":"2005","unstructured":"Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452\u201364. https:\/\/doi.org\/10.1215\/S1152851705000232.","journal-title":"Neuro Oncol"},{"key":"2757_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.11.008","volume":"171","author":"D Ferland-McCollough","year":"2017","unstructured":"Ferland-McCollough D, Slater S, Richard J, Reni C, Mangialardi G. Pericytes, an overlooked player in vascular pathobiology. Pharmacol Ther. 2017;171:30\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.008.","journal-title":"Pharmacol Ther"},{"key":"2757_CR20","doi-asserted-by":"publisher","first-page":"10891","DOI":"10.1038\/srep10891","volume":"5","author":"GN Yin","year":"2015","unstructured":"Yin GN, Das ND, Choi MJ, Song KM, Kwon MH, et al. The pericyte as a cellular regulator of penile erection and a novel therapeutic target for erectile dysfunction. Sci Rep. 2015;5:10891. https:\/\/doi.org\/10.1038\/srep10891.","journal-title":"Sci Rep"},{"key":"2757_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88942","volume":"12","author":"SG Bae","year":"2024","unstructured":"Bae SG, Yin GN, Ock J, Suh JK, Ryu JK, Park J. Single-cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction. Elife. 2024;12:RP88942. https:\/\/doi.org\/10.7554\/eLife.88942.","journal-title":"Elife"},{"key":"2757_CR22","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/diacare.25.12.2159","volume":"25","author":"I S\u00e1enz de Tejada","year":"2002","unstructured":"S\u00e1enz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25:2159\u201364. https:\/\/doi.org\/10.2337\/diacare.25.12.2159.","journal-title":"Diabetes Care"},{"key":"2757_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1743-6109.2009.01587.x","volume":"7","author":"J Angulo","year":"2010","unstructured":"Angulo J, Gonz\u00e1lez-Corrochano R, Cuevas P, Fern\u00e1ndez A, La Fuente JM, Rolo F, et al. Diabetes exacerbates the functional deficiency of NO\/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med. 2010;7:758\u201368. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01587.x.","journal-title":"J Sex Med"},{"issue":"8","key":"2757_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/glycob\/cwx047","volume":"27","author":"M Wakisaka","year":"2017","unstructured":"Wakisaka M, Nagao T. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology. 2017;27(8):691\u20135. https:\/\/doi.org\/10.1093\/glycob\/cwx047.","journal-title":"Glycobiology"},{"issue":"9","key":"2757_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jsxm.2018.07.002","volume":"15","author":"R Assaly","year":"2018","unstructured":"Assaly R, Gorny D, Compagnie S, Mayoux E, Bernabe J, et al. The favorable effect of empagliflozin on erectile function in an experimental model of type 2 diabetes. J Sex Med. 2018;15(9):1224\u201334. https:\/\/doi.org\/10.1016\/j.jsxm.2018.07.002. (Epub 2018 Aug 23 PMID: 30145094).","journal-title":"J Sex Med"},{"issue":"1","key":"2757_CR26","doi-asserted-by":"publisher","first-page":"e15217","DOI":"10.1111\/dme.15217","volume":"41","author":"R Cannarella","year":"2024","unstructured":"Cannarella R, Condorelli RA, Leanza C, Garofalo V, Aversa A, et al. Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: an open-label, non-randomized pilot study. Diabet Med. 2024;41(1):e15217. https:\/\/doi.org\/10.1111\/dme.15217. (Epub 2023 Sep 15. PMID:\u00a037669131).","journal-title":"Diabet Med"},{"key":"2757_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","volume":"3","author":"M Crisan","year":"2008","unstructured":"Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301\u201313. https:\/\/doi.org\/10.1016\/j.stem.2008.07.003. (PMID: 18786417).","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2757_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/ndt\/gfr267","volume":"27","author":"H Noh","year":"2012","unstructured":"Noh H, Yu MR, Kim HJ, Jeon JS, Kwon SH, Jin SY, et al. Uremia induces functional incompetence of bone marrow-derived stromal cells. Nephrol Dial Transplant. 2012;27(1):218\u201325. https:\/\/doi.org\/10.1093\/ndt\/gfr267.","journal-title":"Nephrol Dial Transplant"},{"key":"2757_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.ijir.3900859","volume":"14","author":"GN Yin","year":"2002","unstructured":"Yin GN, Das ND, Choi MJ, Song KM, Kwon MH, Rhoden EL, et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245\u201350. https:\/\/doi.org\/10.1038\/sj.ijir.3900859. (PMID: 12152112).","journal-title":"Int J Impot Res"},{"issue":"9","key":"2757_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21091136","volume":"21","author":"CI Choi","year":"2016","unstructured":"Choi CI. Sodium-Glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents. Molecules. 2016;21(9):1136. https:\/\/doi.org\/10.3390\/molecules21091136.","journal-title":"Molecules"},{"issue":"5","key":"2757_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145\u20139. https:\/\/doi.org\/10.1021\/jm701272q.","journal-title":"J Med Chem"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02757-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:38:42Z","timestamp":1758789522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02757-x","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.\u201d The study protocol was approved by the Kasr Alainy School of Medicine ethical committee, Cairo University, Egypt. Approval number was (N-96-2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. Limitation: Limitations include sample size, the CKD etiology will be considered in future projects. The comparison with PDE5 will be done in further studies and also, more studies are needed to prove the hypothesis of improvement of endothelial dysfunction.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}